Overview

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.

Eligibility

Inclusion Criteria:

• PsA patients as defined by CASPAR criteria
• Patients must be able to comply with the visit schedule, treatment plan, laboratory tests and other study procedures
• Patients must be given informed consent

Exclusion Criteria:

• History of other arthritis within the last 12 months
• Concomitant disease with acute or chronic infectious diseases
• Pregnancy or laction
• Poorly tolerated with venipuncture required for blood sampling during the study